{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:11:29Z","timestamp":1750219889721,"version":"3.41.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":75,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100507","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:54:18Z","timestamp":1742316858000},"page":"100507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5632-3532","authenticated-orcid":false,"given":"Mohamed I","family":"Sharif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad S.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-2120","authenticated-orcid":false,"given":"Ruah","family":"Alyamany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"Alkhaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lrr.2025.100507_bib0001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","article-title":"Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis","volume":"127","author":"Soupir","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.lrr.2025.100507_bib0002","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10428194.2012.701739","article-title":"Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia","volume":"54","author":"Konoplev","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.lrr.2025.100507_bib0003","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/gcc.22936","article-title":"Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study","volume":"60","author":"Orsmark-Pietras","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.lrr.2025.100507_bib0004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.lrr.2025.100507_bib0005","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.leukres.2008.01.012","article-title":"Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma","volume":"32","author":"Ahmed","year":"2008","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.lrr.2025.100507_bib0006","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12301","article-title":"Does BCR\/ABL1 positive acute myeloid leukaemia exist?","volume":"161","author":"Nacheva","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.lrr.2025.100507_bib0007","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/leu.2017.86","article-title":"The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia","volume":"31","author":"Eisfeld","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100507_bib0008","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2025.100507_bib0009","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2025.100507_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of Ponatinib and Blinatumomab in Philadelphia chromosome-positive ALL","author":"Kantarjian","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.lrr.2025.100507_bib0011","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.33529","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.lrr.2025.100507_bib0012","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2025.100507_bib0013","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lrr.2025.100507_bib0014","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2025.100507_bib0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2025.100507_bib0016","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.lrr.2025.100507_bib0017","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.lrr.2025.100507_bib0018","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.lrr.2025.100507_bib0019","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMa"},{"issue":"6","key":"10.1016\/j.lrr.2025.100507_bib0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2025.100507_bib0021","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","article-title":"Olverembatinib treatment in pediatric patients with relapsed Philadelphia-chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2025.100507_bib0022","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1182\/blood-2023-185471","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2025.100507_bib0023","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.lrr.2025.100507_bib0024","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.lrr.2025.100507_bib0025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"355","key":"10.1016\/j.lrr.2025.100507_bib0026","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"15","key":"10.1016\/j.lrr.2025.100507_bib0027","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/cncr.35317","article-title":"Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia","volume":"130","author":"Jabbour","year":"2024","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lrr.2025.100507_bib0028","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","article-title":"Venetoclax-ponatinib for T315I\/compound-mutated ph+ acute lymphoblastic leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.lrr.2025.100507_bib0029","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.26175","article-title":"An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"16_suppl","key":"10.1016\/j.lrr.2025.100507_bib0030","doi-asserted-by":"crossref","first-page":"e19044","DOI":"10.1200\/JCO.2023.41.16_suppl.e19044","volume":"41","author":"Senapati","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:15:11Z","timestamp":1750180511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"alternative-id":["S2213048925000093"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100507","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100507"}}